Revolution Medicines (RVMD) Competitors $54.10 +4.42 (+8.90%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$54.30 +0.20 (+0.37%) As of 10/17/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RVMD vs. ONC, INSM, BNTX, TEVA, GMAB, SMMT, ASND, RDY, VTRS, and ROIVShould you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Revolution Medicines vs. Its Competitors BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Roivant Sciences Revolution Medicines (NASDAQ:RVMD) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment. Does the media refer more to RVMD or ONC? In the previous week, Revolution Medicines had 4 more articles in the media than BeOne Medicines. MarketBeat recorded 15 mentions for Revolution Medicines and 11 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.10 beat Revolution Medicines' score of 0.78 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, RVMD or ONC? Revolution Medicines has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Which has stronger earnings & valuation, RVMD or ONC? Revolution Medicines has higher earnings, but lower revenue than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution Medicines$11.58M873.31-$600.09M-$4.50-12.02BeOne Medicines$3.81B9.10-$644.79M-$1.73-182.90 Is RVMD or ONC more profitable? Revolution Medicines has a net margin of 0.00% compared to BeOne Medicines' net margin of -3.89%. BeOne Medicines' return on equity of -1.22% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -41.78% -35.63% BeOne Medicines -3.89%-1.22%-0.72% Do analysts prefer RVMD or ONC? Revolution Medicines presently has a consensus price target of $76.67, indicating a potential upside of 41.71%. BeOne Medicines has a consensus price target of $340.30, indicating a potential upside of 7.55%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Revolution Medicines is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.93BeOne Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90 Do insiders and institutionals have more ownership in RVMD or ONC? 94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by company insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryRevolution Medicines beats BeOne Medicines on 11 of the 16 factors compared between the two stocks. Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVMD vs. The Competition Export to ExcelMetricRevolution MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.11B$3.44B$6.19B$10.56BDividend YieldN/A2.27%5.70%4.81%P/E Ratio-12.0223.0185.5427.13Price / Sales873.31481.75608.39130.24Price / CashN/A46.9237.1060.81Price / Book4.0210.4112.236.52Net Income-$600.09M-$52.77M$3.33B$276.93M7 Day Performance12.15%2.31%1.17%1.93%1 Month Performance24.25%12.59%6.85%2.19%1 Year Performance7.28%11.18%58.93%34.62% Revolution Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVMDRevolution Medicines4.4092 of 5 stars$54.10+8.9%$76.67+41.7%+7.3%$10.11B$11.58M-12.02250News CoverageAnalyst ForecastInsider TradeHigh Trading VolumeONCBeOne Medicines2.9173 of 5 stars$327.03+2.2%$340.30+4.1%N/A$35.08B$4.56B-189.0311,000INSMInsmed2.9168 of 5 stars$163.94+1.0%$149.06-9.1%+122.4%$34.31B$363.71M-28.711,271News CoveragePositive NewsAnalyst ForecastBNTXBioNTech2.6519 of 5 stars$102.30+0.2%$134.32+31.3%-5.9%$24.54B$2.98B-63.946,772Analyst ForecastTEVATeva Pharmaceutical Industries3.5883 of 5 stars$20.02-0.1%$25.57+27.8%+7.7%$22.97B$16.54B-125.0936,830GMABGenmab A/S3.6396 of 5 stars$32.68+2.7%$40.80+24.8%+44.3%$20.42B$3.12B16.422,682Trending NewsAnalyst ForecastShort Interest ↑Analyst RevisionSMMTSummit Therapeutics3.003 of 5 stars$22.93+7.4%$31.29+36.4%-1.0%$15.86B$700K-22.70110Upcoming EarningsGap DownASNDAscendis Pharma A/S2.8328 of 5 stars$208.43-0.5%$248.29+19.1%+62.0%$12.93B$393.54M-40.391,017News CoverageAnalyst UpgradeAnalyst RevisionGap UpRDYDr. Reddy's Laboratories3.0549 of 5 stars$14.36+0.1%$16.95+18.1%-9.4%$11.97B$3.81B21.7527,811Positive NewsVTRSViatris3.055 of 5 stars$9.86+1.2%$10.40+5.5%-13.5%$11.36B$14.74B-3.4032,000News CoverageAnalyst ForecastROIVRoivant Sciences2.9391 of 5 stars$16.21+1.1%$19.94+23.0%+44.8%$10.95B$29.05M-23.16860Insider Trade Related Companies and Tools Related Companies ONC Alternatives INSM Alternatives BNTX Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives ASND Alternatives RDY Alternatives VTRS Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVMD) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.